NICE wants more info on Roche's MabThera for rare autoimmune disease
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, is so far "minded not" to recommend Roche's MabThera (rituximab) for National Health Service patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. However, Roche could still convince the institute to, say yes. It has asked for more information from ahead of the next appraisal meeting on 28 August .